Circulating Tumor DNA in Advanced Anal Cancer: A Blood Biomarker Goes Viral.

Morris, Van K · Clin Cancer Res · 2019

editorial · Level V

Where this comes from

Abstract

Circulating tumor DNA (ctDNA) as a blood-based biomarker for mutation detection is an exciting, highly sensitive approach in the clinical management of oncology patients. In human papillomavirus-associated malignancies like anal cancer, a viral-specific probe can be utilized for ctDNA detection in the majority of patients to predict clinical outcomes.<i>See related article by Bernard-Tessier et al., p. 2109</i>.

Medical subject headings